 | Up a level |
Cirrincione, Lauren R, Penchala, Sujan Dilly, Scarsi, Kimberly K, Podany, Anthony T, Winchester, Lee C, Back, David J, Khoo, Saye H 
ORCID: 0000-0002-2769-0967, Fletcher, Courtney V, Siccardi, Marco ORCID: 0000-0002-3539-7867 and Else, Laura J
(2018)
Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084.
pp. 106-112.
Cirrincione, Lauren R, Nakalema, Shadia, Chappell, Catherine A, Byakika-Kibwika, Pauline, Kyohairwe, Isabella, Winchester, Lee, Mackline, Hope, Pham, Michelle M, Cohn, Susan E, Siccardi, Marco ORCID: 0000-0002-3539-7867 et al (show 4 more authors)
(2023)
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.
Contraception, 122.
p. 109975.
Neary, Megan ORCID: 0000-0002-4960-2139, Chappell, Catherine A, Scarsi, Kimberly K, Nakalema, Shadia, Matovu, Joshua, Achilles, Sharon L, Chen, Beatrice A, Siccardi, Marco ORCID: 0000-0002-3539-7867, Owen, Andrew ORCID: 0000-0002-9819-7651 and Lamorde, Mohammed
(2019)
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74 (10).
pp. 3003-3010.
Roberts, Owain, Kinvig, Hannah ORCID: 0000-0002-0061-1683, Owen, Andrew ORCID: 0000-0002-9819-7651, Lamorde, Mohammed, Siccardi, Marco ORCID: 0000-0002-3539-7867 and Scarsi, Kimberly K
(2021)
In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.
HIV MEDICINE, 22 (10).
pp. 898-906.
Roberts, Owain, Rajoli, Rajith KR ORCID: 0000-0002-6015-5712, Back, David J, Owen, Andrew ORCID: 0000-0002-9819-7651, Darin, Kristin M, Fletcher, Courtney V, Lamorde, Mohammed, Scarsi, Kimberly K and Siccardi, Marco ORCID: 0000-0002-3539-7867
(2018)
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.
Journal of Antimicrobial Chemotherapy, 73 (4).
pp. 1004-1012.